<DOC>
	<DOCNO>NCT00955214</DOCNO>
	<brief_summary>The utilization paclitaxel-eluting coronary stent small vessel disease effective reduce repeat revascularization major adverse cardiac event within two year follow-up . To evaluate procedural , short long term clinical outcome Taxus Liberte™ Paclitaxel-Eluting Coronary Stent small coronary artery ≤ 2.5 mm reference vessel diameter .</brief_summary>
	<brief_title>Small Coronary Artery Treated TAXUS Liberté Registry Japan</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Angina , Unstable</mesh_term>
	<mesh_term>Angina , Stable</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . Age ≥20 year able undergo CABG 2 . Females pregnant 3 . Patients present angina symptoms myocardial ischemia 4 . Patients available postprocedural observation coronary angiography 24 month 5 . Patients sign patient inform consent 6 . Lesion eligible one 2.5mm paclitaxeleluting stent 7 . De novo lesion nonstented restenosed lesion 1 . Patients contraindicate antiplatelet therapy anticoagulant therapy 2 . Patients significant allergic reaction contrast medium 3 . Chronic total occlusion 4 . Lesion TIMI0 5 . Lesion need two stent 6 . Patients chronic renal failure ( SCr &gt; 3.0mg/dl )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>TAXUS Liberté</keyword>
	<keyword>Small coronary artery disease</keyword>
	<keyword>Paclitaxel-eluting stent</keyword>
</DOC>